
Tokyo-based Editor-in-Chief, Asia-Pacific, for @PharmaScrip @PharmaPinkSheet, @citeline, @NorstellaCo. All views my own, RTs not endorsements.
Tokyo
Joined November 2012
- Tweets9.6K
- Following50
- Followers968
- Likes1.5K
Pinned Tweet
In this week's #podcast: Pfizer’s 2025 policy outlook; made in China blockbusters elusive; Vertex’s pain plans; Q3’s top 10 drugs; and sickle cell disease at ASH. Free access below.
Quick Listen: Scrip’s Five Must-Know Things insights.citeline.com//scrip…
Ian Haydock retweeted
Tanabe Shuts Down NeuroDerm, Along With Approved Parkinson’s Drug
Decision resulted from “a comprehensive review of future strategy” and follows series of other divestment moves by Tanabe since Bain Capital acquisition.
insights.citeline.com/scrip/…
Scrip’s Five Must-Know Things: Rasonque’s Stellar Launch, Biotech Deal Tips, Teva’s Innovation Pivot insights.citeline.com/scrip/…
2
209
$2bn IntraBio Buy Sharpens Shionogi’s Rare Disease Pivot insights.citeline.com/scrip/…
39
This week: who’s setting the M&A pace this year; Roche’s pipeline reset; wet AMD market shakeup; Merck & Co. pulls I-DXd filing; and Merck withdraws Recarbio from the market (free accesss below):
Quick Listen: Scrip’s Five Must-Know Things insights.citeline.com/scrip/…
Novartis Eyes Platform Benefits In $7.2bn Abogen Alliance insights.citeline.com/scrip/…
43
Taiho Draws From Hypomethylating Agent Experience In ASTX030 Program insights.citeline.com/scrip/…
Ian Haydock retweeted
China’s National Medical Products Administration (NMPA) is outpacing the US Food and Drug Administration in the number of novel oncology medicines approved annually, but the FDA remains the leader in approving first-in-class medicines, a new analysis found
insights.citeline.com/pink-s…
Six Chinese Drugs On Course For Blockbuster Status As Five-Year Plan Sets The Bar insights.citeline.com/scrip/…
Ian Haydock retweeted
No Letup In Aging Japan’s Rising Health, Drug Costs
Japan’s latest health and drug spending figures illustrate the dilemma of balancing drug pricing policy with the medical needs of a rapidly aging population.
insights.citeline.com/pink-s…
WCLC 2026: Phase III Overall Survival Win In SCLC For MediLink’s ADC insights.citeline.com/scrip/…
WCLC 2026: Ivonescimab OS Win Sets High Bar For Other Keytruda Rivals In 1L NSCLC insights.citeline.com/scrip/…
Ian Haydock retweeted
Singapore is planning to streamline its health regulatory framework into a single authority, giving companies, innovators and healthcare providers one agency to deal with instead of three. insights.citeline.com/pink-s…
Takeda’s Plump To Retire As R&D Head After Shepherding New Drugs To Market insights.citeline.com/scrip/…
33
Kyowa Kirin Encouraged By nAMD Eye Drop Results Despite Missed Endpoint insights.citeline.com/scrip/…
37
Shionogi Considers Redasemtide’s Future After Mixed Phase II Readouts insights.citeline.com/scrip/…
33
Quick Listen: Scrip’s Five Must-Know Things insights.citeline.com/scrip/…
38
Ian Haydock retweeted
Japan's latest batch of approval recommendations include global-first nods for anselamimab for kappa light chain amyloidosis and gefurulimab for generalized myasthenia gravis.
insights.citeline.com/pink-s…
Remembering Philip Brown, Founder Of Scrip insights.citeline.com/scrip/…
51
Quick Listen: Scrip’s Five Must-Know Things insights.citeline.com/scrip/…
China: Innovation, Deals And The New Rules Of Engagement insights.citeline.com/scrip/…

